Evidence map›Paper›PMID 37924646›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2023

Mapping the European cancer prevention research landscape: A case for more prevention research funding.

Anna Schmutz, Michele Matta, Manon Cairat, Carolina Espina, Joachim Schüz, Ellen Kampman, Morten Ervik, Paolo Vineis, Olaf Kelm

Abstract read
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna SchmutzInternational Agency for Research on Cancer (IARC/WHO), Resource Mobilization Office, 25 Avenue Tony Garnier CS 90627, 69366 Lyon CEDEX 07, France. Electronic address: anna.sch@hotmail.fr.
Michele MattaInternational Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, 25 Avenue Tony Garnier CS 90627, 69366 Lyon CEDEX 07, France.
Manon CairatCentre de Recherche en Epidémiologie et Santé des Populations (CESP), U1018, INSERM, Hôpital Paul Brousse Bat 15/16, 16 Av PV Couturier, 94807 Villejuif Cedex, France.
Carolina EspinaInternational Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, 25 Avenue Tony Garnier CS 90627, 69366 Lyon CEDEX 07, France.
Joachim SchüzInternational Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, 25 Avenue Tony Garnier CS 90627, 69366 Lyon CEDEX 07, France.
Ellen KampmanWageningen University, PO Box 17, 6700 AA Wageningen, Netherlands.
Morten ErvikInternational Agency for Research on Cancer (IARC/WHO), Cancer Surveillance Branch, 25 Avenue Tony Garnier CS 90627, 69366 Lyon CEDEX 07, France.
Paolo VineisMRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Olaf KelmInternational Human Frontier Science Program Organization (HFSPO), 67000 Strasbourg, France.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Despite the strong evidence of prevention as a prime defence against the disease, the majority of cancer research investment continues to be made in basic science and clinical translational research. Little quantitative data is available to guide decisions on the choice of research priorities or the allocation of research resources. The primary aim of the mapping of the European cancer prevention research landscape presented in this paper is to provide the evidence-base to inform future investments in cancer research. Using bibliometric data to identify funders that are active in prevention research in Europe and in the world, we have identified that 14% of cancer research papers had a focus on prevention research and those were funded by 16% of all the European cancer research funders. An important finding of our study is the lack of research on primary prevention with primary prevention funders accounting for 25% of European cancer prevention funders, meaning that less than 4% of all European cancer research funders identified show an interest in primary prevention. An additional analysis revealed that 7% of European cancer prevention research papers are categorised as implementation projects, meaning that only 1% of all cancer research publications are implementation research in cancer prevention. This paper highlights that the narrow focus on biology and treatment in Europe needs to be widened to include such areas as primary prevention and secondary prevention and a larger concentration on implementation research. These data can help support a more policy-focused cancer research agenda for individual European governments and charitable and philanthropic organisations and stimulate joining efforts across Europe to create a more systematic and structured approach to cancer prevention.

Indexed as

Biomedical ResearchNeoplasmsEuropeHealth Services ResearchHumansCancer prevention researchCancer researchEuropean cancer researchInvestments

Identifiers

PMID37924646
PMCPMC10697826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.